Trialsaleniglipronstructure therapeuticsobesitytype 2 diabetesoral glp-1

Structure Therapeutics starts Phase 3 aleniglipron trial in obesity with type 2 diabetes

ACCOMPLISH-2 randomizes adults to multiple maintenance doses of the once-daily oral GLP-1 or placebo for 76 weeks of treatment.

By Priya Raman · Science Reporter

Oct 20 08:00 ETSource: ClinicalTrials.gov

The wire

01NCT07654374, sponsored by Gasherbrum Bio, a wholly owned subsidiary of Structure Therapeutics, is recruiting for a randomized, double-blind, placebo-controlled Phase 3 study that began 17 July 2026.
02Aleniglipron is an oral once-daily small-molecule GLP-1 agonist being positioned for chronic weight management in patients who also have type 2 diabetes.
03The 76-week design will test long-term efficacy, safety and tolerability; no results are available and the trial is still enrolling.

From the source

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
NCT07654374 · PHASE3 · RECRUITING · Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics · Conditions: Obesity, Overweight, Chronic Weight Management.

Read at clinicaltrials.gov

Source URL https://clinicaltrials.gov/study/NCT07654374